Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaya HoldingsKAYS EV-to-EBIT is 0.13 as of Aug. 09, 2026. The stock has 4 warning signs investors should review. Among 684 Drug Manufacturers companies, Kaya Holdings ranks better than 98.1% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Kaya Holdings's Enterprise Value for the quarter that ended in Sep. 2025 was $31.58 Mil.
Kaya Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaya Holdings EV-to-EBIT Related Terms
Kaya Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Kaya Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaya Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaya Holdings EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaya Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kaya Holdings's EV-to-EBIT falls into.
Kaya Holdings's current Enterprise Value is $-1.41 Mil.
Kaya Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.55 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaya Holdings (KAYS) has a EV-to-EBIT of 0.13 as of Aug. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kaya Holdings and its competitors. According to the industry distribution chart, Kaya Holdings ranks #13 out of 684 companies in the Drug Manufacturers industry, placing it in the top 1.9%.
Is Kaya Holdings' EV-to-EBIT too high?
Kaya Holdings' current EV-to-EBIT is 0.13. The Drug Manufacturers industry median EV-to-EBIT is 15.69. Kaya Holdings' value of 0.13 is 99.2% below this industry median. Based on the distribution chart, Kaya Holdings ranks #13 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Kaya Holdings' EV-to-EBIT compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Kaya Holdings ranks #13 out of 684 companies for EV-to-EBIT. This places Kaya Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.69. Kaya Holdings' value of 0.13 is 99.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.69, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaya Holdings's current EV-to-EBIT of 0.13 is 99.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Kaya Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaya Holdings's current EV-to-EBIT is 0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaya Holdings stock overvalued right now?
Kaya Holdings (KAYS) has a current EV-to-EBIT of 0.13. The current EV-to-EBIT is 0.13 and 99.2% below the Drug Manufacturers industry median of 15.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Kaya Holdings (KAYS), the current EV-to-EBIT is 0.13 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kaya Holdings Inc is a holding company. It is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. The company own and operate a medical cannabis dispensary in the United States. Its has produced, distributed, and/or sold a full range of premium cannabis products including flower, oils, vape cartridges and cannabis infused confections, baked goods and beverages through a fully integrated group of subsidiaries and companies supporting distinctive brands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAYS has been successfully added to your 
